⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18676691 | 0.65 | — | — | |
| SCHEMBL8320873 | 0.65 | — | — | |
| SCHEMBL3305167 | 0.65 | — | — | |
| SCHEMBL9045726 | 0.62 | — | — | |
| SCHEMBL21171897 | 0.62 | — | — | |
| SCHEMBL13720958 | 0.62 | — | — | |
| SCHEMBL7396679 | 0.62 | — | — | |
| SCHEMBL22433110 | 0.57 | — | — | |
| SCHEMBL2102767 | 0.57 | — | — | |
| SCHEMBL11045783 | 0.57 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4499106-A2 | NUCLEOSIDE LINE-1 INHIBITORS | Transposon Therapeutics, Inc. (US) | 2025-02-05 | — | — | EP | claimed |
| WO-2023192491-A2 | NUCLEOSIDE LINE-1 INHIBITORS | TRANSPOSON THERAPEUTICS, INC. (US) | 2023-10-05 | — | — | WO | claimed |
| EP-2069390-A2 | OPSIN STABILIZING COMPOUNDS AND METHODS OF USE | University of Florida Research Foundation, Inc. (US) | 2009-06-17 | — | — | EP | claimed |
| WO-2008013983-A2 | OPSIN STABILIZING COMPOUNDS AND METHODS OF USE | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2008-01-31 | — | — | WO | claimed |
| WO-2023033097-A1 | METHOD FOR PRODUCING HETEROCYCLIC SULFONAMIDE DERIVATIVE, AND SYNTHETIC INTERMEDIATE THEREOF | ＥＡファーマ株式会社 | 2023-03-09 | — | — | WO | disclosed |
| CN-110981815-A | Process for producing a compound | PH制药有限公司 | 2020-04-10 | — | — | CN | disclosed |
| EP-3373936-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES FOR TREATING CHRONIC WOUNDS | Bayer Pharma Aktiengesellschaft (DE) | 2018-09-19 | — | — | EP | disclosed |
| CN-107428702-A | Improved process for preparing statin precursors | 中化帝斯曼制药有限公司荷兰公司 | 2017-12-01 | — | — | CN | disclosed |
| WO-2017081044-A1 | 4-(4-CYANO-2-THIOARYL)DIHYDROPYRIMIDINONES FOR TREATING CHRONIC WOUNDS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2017-05-18 | — | — | WO | disclosed |
| CN-105873919-A | Substituted uracils as chymase inhibitors | 拜耳医药股份有限公司 | 2016-08-17 | — | — | CN | disclosed |
| CN-104059024-B | The preparation method of Rosuvastatin intermediate and midbody compound | ZHEJIANG UNIVERSITY (CN) | 2016-04-06 | — | — | CN | disclosed |
| CN-104024241-B | Uracil derivatives and their use for medical purposes | DAINIPPON SUMITOMO PHARMA CO.,LTD. (JP) | 2016-01-20 | — | — | CN | disclosed |
| CN-104059024-A | Preparation method of rosuvastatin intermediate and intermediate compound | UNIV ZHEJIANG | 2014-09-24 | — | — | CN | disclosed |
| EP-2417112-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | Bayer Pharma Aktiengesellschaft (DE) | 2012-02-15 | — | — | EP | disclosed |
| WO-2010115548-A1 | SULFONIC AMIDE AND SULFOXIMINE-SUBSTITUTED DIARYL-DIHYDROPYRIMIDINONES AND USAGE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-10-14 | — | — | WO | disclosed |